Next Phase Newsletter

A healthcare and life sciences branch of a leading manufacturing company invests primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical that has primarily focused on reproductive and maternal health is now looking to expand into other indications. Additionally, the firm is interested in AI drug development platforms. The firm is willing to partner with early to late stage companies, and will partner globally.

The firm is interested in therapeutics in the areas of reproductive and maternal health, and is interested in expanding into the area of GI, such as therapeutics treating IBD and UC, and is interested in the microbiome as well. The firm is interested in all modalities. In addition to therapeutics, the firm is also interested in AI platforms for drug discovery and biomarker identification.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture firm located in the USA has 4 area of focus: fintech, digital health, data analytics and insurtech. The firm has made 36 investments total and the average check size is around $1M in Seed or Series A rounds. The firm’s capital structure is typically SAFEs and priced rounds. The firm also has a second venture fund of $5M for Pre-seed and Seed rounds, and this fund is exclusively for companies located in their state. The firm invests across the US and Canada.

The firm’s main areas of focus are fintech, digital health, data analytics and insurtech. Since the firm is a branch of a legacy life insurance company, within the insurtech and fintech sectors, the firm focuses on the evolution of the consumer wallet and how they can develop new products in partnership with startups. Within the digital health sector, the firm focuses on data collection and items that can influence their underwriting models, electronic med records, wearables, remote monitoring devices, and the firm is looking more into implantables in the future. The firm isn’t interested in physician scaling tools, or any companies focused solely on hardware. The firm is open to pre-prototype companies.

The firm looks for diverse management teams, with 2 or 3 founders. The firm likes to see subject matter expertise, traction in product development or alpha/beta testing, and repeat founders are a plus, but not required. The firm also looks for a strong advisor team. The firm typically co-invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm founded in 2020 focuses on investing, building and scaling life science start ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by numerous angel groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. The firm’s goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. The firm is open to global opportunities.

The firm’s focus on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund based in Los Angeles founded in 2016 is investing out of a $261M fund. The firm invests in many sectors, including cloud-based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm invests in Series A and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning-based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A $50 million venture fund was established the largest health insurer in the state. The focus of the initiative is to develop a portfolio of investments that, as a whole, focus on improving the national health care market, enhance the core business of the company and generate revenue.

These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The firm is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The firm would like to be a strategic partner, as a payer, for startups. The firm prefers early-stage teams backed by experienced management, supported by reputable early-stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A $230 million VC fund was established in 2016 and is based in San Francisco, CA. The fund is independently managed in a strategic partnership with the parent company. The firm invests in early-stage disruptive life science tools, therapeutics, and diagnostic companies. Typical allocations range from $2-10 million initially in a Series A or B round and can be up to $15-20 million over the life span of the company. The firm seeks to syndicate with other leading institutional and strategic investors. The firm expects to make 4-5 new investments over the next 12 months and considers opportunities globally with a focus in the US.

The firm is interested in areas where its expertise and special relationship with the parent company can add value. This includes therapeutics, clinical diagnostics, and life science tools. The firm focuses on applications of genomics including sequencing, assay development, agriculture and environmental science, industrial biotech, digital health, public safety and personal wellness, proteomics and other ‘omics’ areas. The firm prefers pre-revenue companies that have achieved proof-of-concept.

The firm seeks to work with experienced management teams with sector expertise. The firm’s team members have decades of entrepreneurial experience in genomics and may request a board seat depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.